Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

By Pooja Toshniwal Paharia Preclinical studies increasingly place circular RNAs at the intersection of thermogenic programming and organelle stress control, raising the possibility that these stable ...

CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its ...

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Centessa Pharmaceuticals is developing a medicine called ORX750 for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

Indian American researcher developing a novel type of living T cell-based therapy to tackle obesity-induced diabetes ...

Today, the American Diabetes Association(R) (ADA) announced the awardees of the 2026 Pathway to Stop Diabetes(R) (Pathway) Award grants. The seven new awards, totaling $11.3 million in strategic ...

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...

The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...

Scientists are testing whether gene editing might offer a one-time fix for high cholesterol, and approaches being developed ...